首页> 外国专利> Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy

Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy

机译:预测复发缓解型多发性硬化症(RRMS)患者的治疗后预后的方法以及确定新疗法的适用性的方法

摘要

According to the present invention, the amount of a plasmablast (PB) in a sample of a relapsing-remitting multiple sclerosis (RRMS) patient can be measured, thereby predicting the therapeutic effect of interferon beta (IFN-β) or predicting a RRMS case for which the continuous administration of IFN-β is difficult due to the manifestation of a serious adverse reaction or the aggravation of concomitant immune disorder. In addition, the amount of PB in a sample of a RRMS patient can also be measured, thereby predicting the therapeutic effect of an IL-6 inhibitor in the treatment of RRMS. As a result, a treatment method effective for patients not suitable for IFN-β in the treatment of RRMS can be provided.
机译:根据本发明,可以测量复发缓解型多发性硬化症(RRMS)患者的样品中成浆细胞(PB)的量,从而预测干扰素β(IFN-β)的治疗效果或预测RRMS病例由于严重的不良反应或伴随的免疫疾病加重,难以连续给药IFN-β。另外,还可以测量RRMS患者的样品中PB的量,从而预测IL-6抑制剂在RRMS治疗中的治疗效果。结果,可以提供对在RRMS的治疗中不适合IFN-β的患者有效的治疗方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号